2015 American Transplant Congress
Development and Validation of a Genotype Guided Tacrolimus Dosing Equation for African American (AA) Kidney Transplant Recipients
Tacrolimus (tac) has a strong exposure-response relationship with high inter-individual variability in troughs and dose. Tac dose requirements for AA patients are higher than Caucasians,…2015 American Transplant Congress
Calcineurin-Inhibitor Conversion to mTOR Inhibitor in Renal Transplant Recipients Leads to Worse Long Term Clinical Outcomes
We previously reported the short-term feasibility of Calcineurin-Inhibitor (CNI) elimination in kidney transplant recipients. We now report the long-term clinical impact on renal allograft function…2015 American Transplant Congress
Month 48 Follow-Up Results of HERAKLES Trial on Three Different Treatment Regimen and Switching Off Behaviour in De Novo Renal Transplant Patients
1Herakles Study Group, Germany; 2Novartis, Pharma, Germany; 3Herakles Study Group, Switzerland.
Aim: To compare switching off 3 different immunosuppressive (IS) regimen 4years after renal transplantation (Tx).Methods: 802 patients (pts) were included in this prospective, open-label, randomized,…2015 American Transplant Congress
Deceased Donor Kidney Transplantation Without Calcineurin Inhibitors or Steroids
1Transplant Center, Emory University, Atlanta, GA; 2Surgery, Duke University, Durham, NC.
Kidney transplantation remains limited by toxicities of calcineurin inhibitors (CNIs) and steroids. Belatacept is a less toxic CNI alternative delivered by monthly intravenous infusion, but…2015 American Transplant Congress
Defining the Role of CD57+CD4 T Cells in Belatacept-Resistant Rejection
1Duke University, Durham, NC; 2Emory University, Atlanta, GA; 3Bristol-Myers Squibb, Princeton, NJ.
Purpose: We have shown that CD57+PD1- CD4 T cells are present in higher numbers in the peripheral blood and allograft biopsies of patients who experienced…2015 American Transplant Congress
ASKP1240 in De Novo Kidney Transplant Recipients
Primary objective was to evaluate the efficacy and safety of ASKP1240, antagonistic anti-CD40 antibody, in either a CNI free regimen or a CNI minimization regimen…2015 American Transplant Congress
Pharmacist-Led Renal-Sparing Conversion to Everolimus After Liver Transplantation
1Barnes-Jewish Hospital, St. Louis, MO; 2Washington University in St. Louis, St. Louis, MO.
Purpose: Preservation of renal function following orthotopic liver transplantation (OLT) through calcineurin inhibitor (CNI)-minimization is an established clinical objective. The use of everolimus (EVR) to…2015 American Transplant Congress
Immunomodulation of Human T Cells by a Novel RALG Preparation With Higher Specificity Toward Activating T Cells
Surgery, Duke University Medical Center, Durham, NC.
Current induction therapy using thymoglobulin (ATG) results in nonspecific T cell depletion. We have generated a polyclonal rabbit anti-human leukocyte globulin (RALG) by immunizing rabbits…2015 American Transplant Congress
Third Party Mesenchymal Stromal Cell Infusion in Kidney Transplant Recipient: 6-Month Safety Interim Analysis
Back-groundMesenchymal stromal cell (MSC) have immunomodulating properties and could be used as immunosuppressive agents.We report the 6-month safety results for the 5 first patients treated…2015 American Transplant Congress
Pharmacogenomic Predictors of Acute Rejection in Kidney Transplant Recipients Identified Using a DNA Biobank Linked to Electronic Medical Records
Purpose: Risk for acute rejection (AR) complicating transplant immunosuppression may be affected by frequent variants in pharmacogenes. Using a DNA biobank linked to electronic medical…
American Transplant Congress abstracts